SCHEMBL25779359

SCHEMBL25779359

CCOC(C)CCOCCOCCCS

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25779331 0.94 MEN1 (0.31) LMNA
SCHEMBL28433372 0.83 LMNA (0.43) LMNA
SCHEMBL25779349 0.81 LMNA (0.31) LMNA
SCHEMBL25779354 0.81 MEN1 (0.39) LMNA
SCHEMBL25779336 0.79 MEN1 (0.42) LMNA
SCHEMBL25779389 0.79 CYP3A4 (0.36) LMNA
SCHEMBL26743666 0.78 LMNA (0.35) LMNA
SCHEMBL13081849 0.77 TDP1 (0.42) LMNA
SCHEMBL6492390 0.77 LMNA (0.41) LMNA
SCHEMBL25779374 0.76 LMNA (0.33) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212103-A1 POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF HANMI PHARM. CO., LTD. (KR) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212103-A1 POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF RPN2, MPDU1, RPN1 LMNA 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.